List of Lexette drug patents
Lexette is owned by Mayne Pharma.
Lexette contains Halobetasol Propionate.
Lexette has a total of 3 drug patents out of which 0 drug patents have expired.
Lexette was authorised for market use on 24 May, 2018.
Lexette is available in aerosol, foam;topical dosage forms.
Lexette can be used as for the topical treatment of plaque psoriasis in patients 18 years of age and older.
The generics of Lexette are possible to be released after 30 May, 2037.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020407 | MAYNE PHARMA | Corticosteroid containing foam compositions and method of manufacture thereof |
Nov, 2036
(13 years from now) | |
| US10857159 | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
Nov, 2036
(13 years from now) | |
|
US10857159
(Pediatric) | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
May, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Aug 18, 2024 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 24 May, 2018
Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older
Dosage: AEROSOL, FOAM;TOPICAL
LEXETTE family patents
8
United States
2
Singapore
2
Japan
2
Brazil
2
Philippines
2
IB
2
EA
2
Canada
2
Mexico
2
Australia
2
Korea, Republic of
2
China
2
European Union
1
Malaysia
1
Spain
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic